Protagonist Therapeutics, Inc (PTGX) /
The cash flow of Protagonist Therapeutics, Inc over the past 10 years
Chart Protagonist Therapeutics, Inc: operating cash flow, capital expenditures, free cash flow, fiscal 2016–2025 Open the chart →In fiscal 2025, the latest fiscal year on file, Protagonist Therapeutics, Inc's operating cash flow was $57.67M and its capital expenditures $1.59M, leaving free cash flow of $56.08M. Free cash flow was above zero in 3 of the 10 years shown. It ranged from -$108.97M in fiscal 2021 to $182.8M in fiscal 2024. Capital expenditures were highest in fiscal 2025, at $1.59M.
Year by year
| Fiscal year | Operating cash flow | Capital expenditures | Free cash flow* |
|---|---|---|---|
| 2025ended Dec 31, 2025 | $57.67M | $1.59M | $56.08M |
| 2024ended Dec 31, 2024 | $184.15M | $1.35M | $182.8M |
| 2023ended Dec 31, 2023 | -$70.24M | $609K | -$70.84M |
| 2022ended Dec 31, 2022 | -$108.14M | $795K | -$108.93M |
| 2021ended Dec 31, 2021 | -$107.86M | $1.1M | -$108.97M |
| 2020ended Dec 31, 2020 | -$72.48M | $471K | -$72.95M |
| 2019ended Dec 31, 2019 | -$41.53M | $967K | -$42.49M |
| 2018ended Dec 31, 2018 | -$49.95M | $486K | -$50.43M |
| 2017ended Dec 31, 2017 | $3.87M | $666K | $3.21M |
| 2016ended Dec 31, 2016 | -$29.97M | $347K | -$30.32M |
Fiscal years as Protagonist Therapeutics, Inc reports them. * Calculated by us from the company's filed figures; — no figure on file. From SEC filings, updated nightly. How each line is read.
More on Protagonist Therapeutics, Inc
- The revenue of Protagonist Therapeutics, Inc
- The profitability of Protagonist Therapeutics, Inc
- The debt of Protagonist Therapeutics, Inc
- All of Protagonist Therapeutics, Inc's financials, charted
Companies of a similar size
Not investment advice. This page shows what Protagonist Therapeutics, Inc filed with the SEC. Nothing here is a recommendation about any security. Check important figures against the company's own filings.